A 2020 report from the National Academies of Sciences, Engineering, and Medicine concluded that compounded bioidentical hormone therapy lacks the clinical evidence to support widespread use, and the finding still shapes how FDA and state boards look at every cBHT prescription written today. For compounding pharmacists, the report's fallout runs through prescribing scope, the substances FDA is weighing for a compounding-restriction list, and the inspection findings state boards now cite as precedent.
The NASEM Report's Core Finding
The committee, convened by the National Academies at FDA's request and publishing its findings on July 1, 2020, reviewed the available evidence on compounded bioidentical hormone therapy (cBHT) and reported insufficient evidence to support its clinical utility for widespread use. The report recommended prescribers restrict cBHT to two circumstances: a documented allergy or hypersensitivity to an ingredient in an FDA-approved hormone product, or a need for a dosage form or strength that no FDA-approved product offers. The committee characterized widespread cBHT use outside those circumstances as a public health concern, and every other cBHT prescription, in that framing, is a preparation without an approved-product justification, the exact gap FDA and state boards of pharmacy now look for when they review dispensing records.
The Hormones Nominated for FDA Review
The report also directed FDA's Pharmacy Compounding Advisory Committee to evaluate specific bioidentical hormones, and eleven substances, including estradiol, estrone, estriol, progesterone, pregnenolone, and testosterone in cypionate and propionate forms, have been nominated for FDA's difficult-to-compound list. That list is part of the rulemaking FDA has been developing under the Drug Quality and Security Act since 2013, and placement on it would bar 503A/503B compounding of the named substances outright, unless the pharmacy can fit the preparation into a different statutory exemption. FDA has not finalized that step for cBHT as of this writing, but pellet formulations of these hormones drew separate scrutiny in the report over stability and dosing documentation gaps.
A compounding pharmacy that cannot document medical necessity for a compounded hormone is defending a business decision, not a clinical one.
The Current Enforcement Posture
FDA has not finalized the difficult-to-compound list, but 2025 and 2026 enforcement shows the agency is not waiting on rulemaking to act. Recent warning letters to 503B outsourcing facilities have cited current good manufacturing practice (cGMP) violations, USP 797/800 sterile compounding lapses, and missing adverse event reports tied to sterile hormone and GLP-1 preparations. A 2026 recall of more than 100,000 estradiol pellets over contamination risk shows how a single lot can trigger a facility-wide inspection. State boards of pharmacy are running a parallel track, pulling prescribing records and beyond-use date documentation for cBHT dispensing the same way they already do for controlled substances. The posture extends beyond hormones: FDA's April 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and the Pharmacy Compounding Advisory Committee's July 2026 vote on nominated peptides, both point to an agency narrowing what it treats as a legitimate compounding need across the board.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving an FDA Form 483, a warning letter, or a state board inquiry tied to bioidentical hormone dispensing. Early legal intervention can protect the pharmacy's rights, shape how inspection findings and prescriber documentation are presented in the response, preserve relevant defenses, and let counsel communicate with FDA or the board on the pharmacy's behalf. Waiting until a proposed action is issued can mean defending decisions and paperwork gaps that were already made without legal input.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies and prescribers through FDA warning letter response, state board inspections, and the documentation review that separates a defensible cBHT dispensing pattern from one that reads as a business decision without medical necessity, as part of the firm's compounding pharmacy defense practice. If your pharmacy dispenses bioidentical hormone preparations and needs to confirm the record supports every prescription, contact us for a free, confidential consultation.
